Literature DB >> 16189731

[Questions and theses of pharmacological therapeutic options of Alzheimer's dementia with acetylcholinesterase inhibitors].

H van den Bussche1.   

Abstract

The paper reviews the evidence for the recommendation of cholinesterase inhibitors and asks critical questions concerning the reasons for the discrepancy between the weak evidence and the recommendation of these drugs in therapy guidelines. Furthermore, the argument of the severe underuse of these drugs is examined.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189731     DOI: 10.1007/s00391-005-1105-0

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN: 0948-6704            Impact factor:   1.281


  4 in total

1.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

Authors:  C Courtney; D Farrell; R Gray; R Hills; L Lynch; E Sellwood; S Edwards; W Hardyman; J Raftery; P Crome; C Lendon; H Shaw; P Bentham
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

Review 2.  Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.

Authors:  Hanna Kaduszkiewicz; Thomas Zimmermann; Hans-Peter Beck-Bornholdt; Hendrik van den Bussche
Journal:  BMJ       Date:  2005-08-06

3.  [Treatment of Alzheimer's disease utilising the best available evidence-based medicine -- utopia?].

Authors:  G Stoppe; O Pirk; M Haupt
Journal:  Gesundheitswesen       Date:  2005-01

Review 4.  [Doubtful evidence for the use of the cholinesterase inhibitor donepezil in patients with dementia--a systematic review].

Authors:  H Kaduszkiewicz; H-P Beck-Bornholdt; H van den Bussche; T Zimmermann
Journal:  Fortschr Neurol Psychiatr       Date:  2004-10       Impact factor: 0.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.